Promising Activities of Marine Natural Products against Hematopoietic Malignancies
According to the WHO classification of tumors, more than 150 typologies of hematopoietic and lymphoid tumors exist, and most of them remain incurable diseases that require innovative approaches to improve therapeutic outcome and avoid side effects. Marine organisms represent a reservoir of novel bio...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/6/645 |
id |
doaj-09238b65d3ef460fbc2eee084144d3fe |
---|---|
record_format |
Article |
spelling |
doaj-09238b65d3ef460fbc2eee084144d3fe2021-06-30T23:24:06ZengMDPI AGBiomedicines2227-90592021-06-01964564510.3390/biomedicines9060645Promising Activities of Marine Natural Products against Hematopoietic MalignanciesAssunta Saide0Sara Damiano1Roberto Ciarcia2Chiara Lauritano3Marine Biotechnology Department, Stazione Zoologica Anton Dohrn, Villa Comunale, 80121 Napoli, ItalyDepartment of Veterinary Medicine and Animal Productions, University of Naples “Federico II”, 80137 Naples, ItalyDepartment of Veterinary Medicine and Animal Productions, University of Naples “Federico II”, 80137 Naples, ItalyMarine Biotechnology Department, Stazione Zoologica Anton Dohrn, Villa Comunale, 80121 Napoli, ItalyAccording to the WHO classification of tumors, more than 150 typologies of hematopoietic and lymphoid tumors exist, and most of them remain incurable diseases that require innovative approaches to improve therapeutic outcome and avoid side effects. Marine organisms represent a reservoir of novel bioactive metabolites, but they are still less studied compared to their terrestrial counterparts. This review is focused on marine natural products with anticancer activity against hematological tumors, highlighting recent advances and possible perspectives. Until now, there are five commercially available marine-derived compounds for the treatment of various hematopoietic cancers (e.g., leukemia and lymphoma), two molecules in clinical trials, and series of compounds and/or extracts from marine micro- and macroorganisms which have shown promising properties. In addition, the mechanisms of action of several active compounds and extracts are still unknown and require further study. The continuous upgrading of omics technologies has also allowed identifying enzymes with possible bioactivity (e.g., <span style="font-variant: small-caps;">l</span>-asparaginase is currently used for the treatment of leukemia) or the enzymes involved in the synthesis of bioactive secondary metabolites which can be the target of heterologous expression and genetic engineering.https://www.mdpi.com/2227-9059/9/6/645leukemiamarine organismsmarine biotechnologymarine natural productsanticancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Assunta Saide Sara Damiano Roberto Ciarcia Chiara Lauritano |
spellingShingle |
Assunta Saide Sara Damiano Roberto Ciarcia Chiara Lauritano Promising Activities of Marine Natural Products against Hematopoietic Malignancies Biomedicines leukemia marine organisms marine biotechnology marine natural products anticancer |
author_facet |
Assunta Saide Sara Damiano Roberto Ciarcia Chiara Lauritano |
author_sort |
Assunta Saide |
title |
Promising Activities of Marine Natural Products against Hematopoietic Malignancies |
title_short |
Promising Activities of Marine Natural Products against Hematopoietic Malignancies |
title_full |
Promising Activities of Marine Natural Products against Hematopoietic Malignancies |
title_fullStr |
Promising Activities of Marine Natural Products against Hematopoietic Malignancies |
title_full_unstemmed |
Promising Activities of Marine Natural Products against Hematopoietic Malignancies |
title_sort |
promising activities of marine natural products against hematopoietic malignancies |
publisher |
MDPI AG |
series |
Biomedicines |
issn |
2227-9059 |
publishDate |
2021-06-01 |
description |
According to the WHO classification of tumors, more than 150 typologies of hematopoietic and lymphoid tumors exist, and most of them remain incurable diseases that require innovative approaches to improve therapeutic outcome and avoid side effects. Marine organisms represent a reservoir of novel bioactive metabolites, but they are still less studied compared to their terrestrial counterparts. This review is focused on marine natural products with anticancer activity against hematological tumors, highlighting recent advances and possible perspectives. Until now, there are five commercially available marine-derived compounds for the treatment of various hematopoietic cancers (e.g., leukemia and lymphoma), two molecules in clinical trials, and series of compounds and/or extracts from marine micro- and macroorganisms which have shown promising properties. In addition, the mechanisms of action of several active compounds and extracts are still unknown and require further study. The continuous upgrading of omics technologies has also allowed identifying enzymes with possible bioactivity (e.g., <span style="font-variant: small-caps;">l</span>-asparaginase is currently used for the treatment of leukemia) or the enzymes involved in the synthesis of bioactive secondary metabolites which can be the target of heterologous expression and genetic engineering. |
topic |
leukemia marine organisms marine biotechnology marine natural products anticancer |
url |
https://www.mdpi.com/2227-9059/9/6/645 |
work_keys_str_mv |
AT assuntasaide promisingactivitiesofmarinenaturalproductsagainsthematopoieticmalignancies AT saradamiano promisingactivitiesofmarinenaturalproductsagainsthematopoieticmalignancies AT robertociarcia promisingactivitiesofmarinenaturalproductsagainsthematopoieticmalignancies AT chiaralauritano promisingactivitiesofmarinenaturalproductsagainsthematopoieticmalignancies |
_version_ |
1721351404995477504 |